literature

HIV mutation literature information.

Energetics of mutation-induced changes in potency of lersivirine against HIV-1 reverse transcriptase.

PMID: 22574920 2012 The journal of physical chemistry. B

Abstract: The dissociation constant is decreased for the Y188C and G190A (2-fold), the M184V (5-fold), and the Y188C/Y188C mutant (10-fold), due to stronger electrostatic interactions between LRV and RT.

Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.

PMID: 22984494 2012 PloS one

Discussion: Thus far, about 32 NVP-resistance associated mutations in 17 positions, including 15 major NVP-resistant mutations at 5 positions (K103NST, V106AM, Y181CIV, Y188LHC, G190ASEQ), have been summarized in HIV drug resistance database of Stanford University.

Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.

PMID: 21487249 2011 AIDS (London, England)

Result: Five infants had NVP resistance mutations other than K103N and Y181C detected by ViroSeq at 14 weeks (V106A, Y188C/L, G190A) in the absence of K103N or Y181C.

Discussion: Five infants had other NVP resistance mutations detected at 14 weeks of age in the absence of K103N or Y181C (

Discussion: However, a previous study suggests that some of those mutations (V106M, Y188C, G190A) may be less likely to persist at high levels in infants after NVP exposure than K103N and Y181C.

HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

PMID: 21633285 2011 AIDS (London, England)

Result: One sample had both K103N and Y188C by population genotype, otherwise multiple major NNRTI mutations were not found.

Result: Other major NNRTI mutations V106M, Y188C and G190A were found in a small proportion of infants under 12 months but were absent in older children.

Result: The G190A and Y188C mutations were each detected in 2 samples and V106I/M in 1 sample.

High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo.

PMID: 21663632 2011 Journal of the International AIDS Society

Result: V106A/M, K101E and Y188C/L were noted in four, three and two patients, respectively.

Table: Y188C

Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.

PMID: 21694608 2011 Journal of acquired immune deficiency syndromes (1999)

Result: K103N was the most commonly detected in 9 (25%) participants, V106M in 6 (16.7%), and G190S/A +/- Y188C/L in 6 (16.7%).

Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing.

PMID: 21799767 2011 PloS one

Result: On the other hand the NVP-resistant strain Y188C X403-4 resulted in a mean of 8.4 (range 6.9-9.7) for 3TC and 1.9 (range 1.3-2.7) for NVP.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

PMID: 22132100 2011 PloS one

Method: RT mutations were identified from the International AIDS Society USA Drug (IAS-USA) mutation tables, spring 2008 (http://www.iasusa.org/resistance_mutations): M41L, K65R, D67N, insertion 69, K70R/E, L74I/V, L100I, K103N, V106A/M, V108I, Q151M, Y181I/C, M184V, Y188C/L, G190A/S, L210W, T215Y/F,

PMID: 19915448 2010 AIDS (London, England)

Abstract: Postpartum nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance rates among women receiving nevirapine were 25% for K103N (37.5% by ASPCR) and 12.5% for Y188C.

Result: Using population sequencing of plasma viruses, the postpartum rates of NNRTI resistance among the eight women receiving nevirapine were: 25% [95% CI: 3.2%-65.1%] for K103N (2 cases), and 12.5%% [95% CI: 0.3%-52.7%] for Y188C (1 case).

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

PMID: 20102272 2010 The Journal of infectious diseases

Method: For single-genome sequencing analyses, a total of 27 subjects (15 NNRTI-naive and 12 NNRTI-experienced) were randomly selected from enrollees meeting the following criteria: i) entry sample negative for NNRTI-resistance mutations by standard genotype analysis (ViroSeq platform; Celera, Alameda, CA); ii) reached a protocol-defined virologic failure endpoint by study week 24, and iii) the virologic failure sample had one or more major NNRTI-resistance mutations (L100I, K101E, K103N, V106A or M, V108I, Y181C or I, Y188C, H, or L, G

Browser Board

Co-occurred Entities

Filtrator